Payment overview · 2025
General Payments
$307.15
17 reported records · 10 companies
Healthcare provider profile · identity verified
Allan W Tramp, MD
Allopathic & Osteopathic Physicians|Family Medicine · FALLS CITY, NE · NPI 1316990278
Verified facts
What the public records show
CMS Open Payments records show Allan W Tramp, MD received $307.15 in general payments during 2025 across 17 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $65.29 | 21.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.12 | 14.0% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $40.73 | 13.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.71 | 11.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.86 | 11.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.42 | 8.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.56 | 5.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.60 | 5.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.29 | 5.0% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $14.57 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $307.15 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $65.29 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.12 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.12 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $40.73 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.71 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.42 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
315 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 845 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 473 | 75 |
| Furosemide | Furosemide | 444 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 431 | 80 |
| Potassium Chloride | Potassium Chloride | 396 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 345 | 49 |
| Lisinopril | Lisinopril | 339 | 64 |
| Gabapentin | Gabapentin | 329 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 324 | 51 |
| Eliquis | Apixaban | 315 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 312 | 67 |
| Metformin Hcl | Metformin Hcl | 295 | 48 |
| Losartan Potassium | Losartan Potassium | 286 | 63 |
| Montelukast Sodium | Montelukast Sodium | 228 | 43 |
| Famotidine | Famotidine | 219 | 38 |
| Tramadol Hcl | Tramadol Hcl | 213 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 212 | 43 |
| Carvedilol | Carvedilol | 210 | 28 |
| Allopurinol | Allopurinol | 208 | 30 |
| Donepezil Hcl | Donepezil Hcl | 197 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 196 | 30 |
| Meloxicam | Meloxicam | 192 | 40 |
| Omeprazole | Omeprazole | 177 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 169 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 36 |
| Spironolactone | Spironolactone | 166 | 31 |
| Glimepiride | Glimepiride | 164 | 26 |
| Sertraline Hcl | Sertraline Hcl | 162 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 23 |
| Lorazepam | Lorazepam | 155 | 31 |
| Prednisone | Prednisone | 155 | 58 |
| Pregabalin | Pregabalin | 154 | 25 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 144 | 21 |
| Warfarin Sodium | Warfarin Sodium | 144 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 29 |
| Buspirone Hcl | Buspirone Hcl | 132 | 21 |
| Torsemide | Torsemide | 126 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 23 |
| Trazodone Hcl | Trazodone Hcl | 121 | 20 |
| Finasteride | Finasteride | 119 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 118 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 102 | 15 |
| Simvastatin | Simvastatin | 101 | 21 |
| Jardiance | Empagliflozin | 93 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 85 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | suppressed |
| Cephalexin | Cephalexin | 85 | 35 |
| Morphine Sulfate Er | Morphine Sulfate | 85 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 85 | 12 |
| Alprazolam | Alprazolam | 84 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 18 |
| Fentanyl | Fentanyl | 81 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 79 | 14 |
| Celecoxib | Celecoxib | 76 | suppressed |
| Xarelto | Rivaroxaban | 75 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 73 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | suppressed |
| Tradjenta | Linagliptin | 68 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 38 |
| Linzess | Linaclotide | 65 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 61 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 60 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 58 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | suppressed |
| Azithromycin | Azithromycin | 57 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 56 | suppressed |
| Mirtazapine | Mirtazapine | 56 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 56 | 14 |
| Levetiracetam | Levetiracetam | 55 | suppressed |
| Nystatin | Nystatin | 55 | 23 |
| Novolog Flexpen | Insulin Aspart | 54 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 17 |
| Farxiga | Dapagliflozin Propanediol | 52 | suppressed |
| Trimethoprim | Trimethoprim | 52 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 50 | suppressed |
| Sucralfate | Sucralfate | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 48 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | suppressed |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 48 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Ezetimibe | Ezetimibe | 46 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Dutasteride | Dutasteride | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Naproxen | Naproxen | 39 | 11 |
| Estradiol | Estradiol | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 16 |
| Atenolol | Atenolol | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 35 | suppressed |
| Dexamethasone | Dexamethasone | 34 | 13 |
| Primidone | Primidone | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 30 | 26 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Budesonide | Budesonide | 29 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 17 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 18 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Haloperidol | Haloperidol | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Letrozole | Letrozole | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Indomethacin | Indomethacin | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 16 | suppressed |
| Trulance | Plecanatide | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Isibloom | Desogestrel-Ethinyl Estradiol | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Salsalate | Salsalate | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $307.15 · 17 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, EVENITY, FANAPT, ImmunoCAP, LEQVIO, MOUNJARO, NURTEC ODT, REXULTI, VRAYLAR, YUPELRI, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error